Thank You!

Thank You!

We will keep you updated

In the meantime, follow us on our social media and see other Median contents that may interest you

    • The latest from Median

    Median Technologies has officially commenced operations with all investigator sites participating in the pivotal validation plan for its iBiopsy® Lung Cancer Screening (LCS) AI/ML tech-based CADe/CADx Software as Medical Device (SaMD).
    Read more
    Median reports today its business indicators for the first half of 2023 for the iCRO activity and the iBiopsy® activity. The Company also announces the first step of ths refinancing plan.
    Read more
    The study showed that CT-based radiomics can accurately predict the histopathological subtype of NSCLC patients, offering a less invasive and more cost-effective alternative to traditional tissue analysis methods.
    Read more
    AI-powered medical image analysis has the potential to serve as predictive biomarkers for guiding targeted therapies in the future
    Read more
    Median will be exhibiting at the ESMO Congress on October 20 – 24 in Madrid. Happy to see you there at IFEMA Madrid, Hall 5, booth #522!
    Read more

    Conferences

    20 – 24 October, 2023

    ESMO 2023

    Median will be exhibiting at the ESMO Congress on October 20 – 24 in Madrid. Happy to see you there at IFEMA Madrid, Hall 5, booth #522!

    See all conferences
    Insights